Tocilizumab in the treatment of active chronic humoral rejection resistant to standard therapy

Tocilizumab in the treatment of active chronic humoral rejection resistant to standard therapy

Introduction: There is no consensus on the most appropriate treatment for chronic active antibody-mediated rejection (cAMR). Recent studies suggest that treatment with tocilizumab (TCZ) may stabilize graft function, decrease the intensity of donor-specific HLA antibodies (DSAs) and reduce inflammati...

Full description

Bibliographic Details
Main Authors: Betty Chamoun, Pablo Sánchez-Sancho, Irina B. Torres, Alejandra Gabaldon, Manel Perelló, Joana Sellarés, Francesc Moreso, Daniel Serón
Format: Article
Language:English
Published: Elsevier 2022-09-01
Series:Nefrología (English Edition)
Subjects:
Rechazo humoral crónico activo
Tocilizumab
Trasplante renal
Anticuerpos donante-específicos
Filtrado glomerular
Online Access:http://www.sciencedirect.com/science/article/pii/S2013251423000147

Internet

http://www.sciencedirect.com/science/article/pii/S2013251423000147

Similar Items